ClinVar Miner

Submissions for variant NM_004360.5(CDH1):c.13A>G (p.Ser5Gly)

dbSNP: rs1555509637
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000559657 SCV000637718 uncertain significance Hereditary diffuse gastric adenocarcinoma 2017-03-02 criteria provided, single submitter clinical testing This sequence change replaces serine with glycine at codon 5 of the CDH1 protein (p.Ser5Gly). The serine residue is weakly conserved and there is a small physicochemical difference between serine and glycine. In summary, this variant is a novel missense change that is not predicted to affect protein function. There is no indication that it causes disease, but the available evidence is currently insufficient to prove that conclusively. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. While this variant is not present in population databases, the frequency information is unreliable, as metrics indicate poor data quality at this position in the ExAC database. This variant has not been reported in the literature in individuals with a CDH1-related disease.
Ambry Genetics RCV002395361 SCV002697718 uncertain significance Hereditary cancer-predisposing syndrome 2023-10-23 criteria provided, single submitter clinical testing The p.S5G variant (also known as c.13A>G), located in coding exon 1 of the CDH1 gene, results from an A to G substitution at nucleotide position 13. The serine at codon 5 is replaced by glycine, an amino acid with similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 4400 samples (8800 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.001% (greater than 105,000 alleles tested) in our clinical cohort. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of p.S5G remains unclear.
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein RCV000559657 SCV003807626 uncertain significance Hereditary diffuse gastric adenocarcinoma 2022-10-14 criteria provided, single submitter clinical testing ACMG classification criteria: PM2 moderated, BP4 supporting

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.